AbbVie (NYSE:ABBV) Shares Up 2% – Time to Buy?

AbbVie Inc. (NYSE:ABBV)’s share price shot up 2% during trading on Tuesday . The company traded as high as $219.17 and last traded at $217.3880. 8,170,519 shares changed hands during mid-day trading, an increase of 11% from the average session volume of 7,365,347 shares. The stock had previously closed at $213.12.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: BMO Capital maintained a Buy rating and $258 price target, reiterating confidence in AbbVie’s immunology strength and acquisition strategy — a visible analyst endorsement supporting investor demand. Article Title
• Positive Sentiment: Institutional buying: Beacon Investment Advisory increased its stake in AbbVie in Q4, signaling incremental shareholder support that can underpin the stock. Article Title
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) rolled out a consumer promotion (CoolMonth deals) and presented safety/efficacy data at AAD — actions that can boost aesthetics revenue and patient demand in the near term. Article Title
• Neutral Sentiment: AbbVie scheduled its Q1 2026 earnings release and conference call for April 29 — an upcoming catalyst that can drive volatility as investors reposition ahead of results and updated guidance. Article Title
• Neutral Sentiment: Broader obesity/peptide drug race coverage (PatentVest report on amylin programs) highlights shifting market dynamics in metabolic medicine that could reallocate R&D and M&A focus across pharma, including implications for AbbVie’s portfolio positioning. Article Title
• Negative Sentiment: Zacks flags near-term pressure in AbbVie’s oncology sales mix — Imbruvica pricing headwinds may weigh on top-line growth in 2026 despite contributions from newer oncology drugs. Article Title
• Negative Sentiment: Competitive pressure in dermatology: J&J’s launch of Icotyde raises rivalry for AbbVie’s Skyrizi, though AbbVie publicly asserts Skyrizi’s efficacy edge — competition could compress market share/pricing over time. Article Title

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ABBV. Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. Berenberg Bank set a $275.00 price target on shares of AbbVie in a research note on Tuesday, January 20th. UBS Group lowered their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Evercore dropped their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Stock Performance

The firm has a 50 day simple moving average of $221.93 and a two-hundred day simple moving average of $224.66. The firm has a market capitalization of $384.38 billion, a P/E ratio of 92.11, a PEG ratio of 0.73 and a beta of 0.34.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Insider Activity at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.08% of the stock is owned by company insiders.

Institutional Investors Weigh In On AbbVie

Several large investors have recently made changes to their positions in ABBV. Evolution Wealth Management Inc. bought a new position in AbbVie during the second quarter valued at about $26,000. Chelsea Counsel Co. bought a new position in shares of AbbVie during the 3rd quarter valued at approximately $26,000. Litman Gregory Wealth Management LLC purchased a new stake in shares of AbbVie during the 4th quarter worth approximately $28,000. Westend Capital Management LLC bought a new stake in shares of AbbVie in the 4th quarter worth approximately $29,000. Finally, Imprint Wealth LLC raised its holdings in shares of AbbVie by 56.3% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.